So Jeong Kim

Ms. So Jeong Kim

Yonsei University College of Medicine, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SKSo Jeong Kim
So Jeong Kim
JCJun-Won Chung
Jun-Won Chung
HWHyun Sun Woo
Hyun Sun Woo
SKSu Young Kim
Su Young Kim
JKJung Ho Kim
Jung Ho Kim
DPDong Kyun Park
Dong Kyun Park
Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial


15 September 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
GLGalam Leem
Galam Leem
MSMin Je Sung
Min Je Sung
JPJi Hoon Park
Ji Hoon Park
SKSo Jeong Kim
So Jeong Kim
JJJung Hyun Jo
Jung Hyun Jo
MCMoon Jae Chung
Moon Jae Chung
INTRODUCTION: The incidence of postendoscopic retrograde cholangiopancreatography (ERCP) infections is reported to be up to 18% in patients with biliary obstruction. Antibiotic prophylaxis may reduce the risk of infectious complications after ERCP; however, the clinical value of prophylactic antibiotics in ERCP remains controversial. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to investigate whether the use of prophylactic antibiotics would reduce infectious complications after ERCP in patients with biliary obstruction. We randomly assigned patients in a 1:1 ratio to receive either a single dose of 1 g intravenous cefoxitin or normal saline as a placebo 30 minutes before undergoing ERCP. The primary outcome was the incidence of infectious complications after ERCP. RESULTS: We enrolled 378 patients, and 189 patients were assigned to each group. The risk of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11–0.74, P = 0.0073). The incidence rates of bacteremia were 2.3% (4 of 176 patients) and 6.4% (11 of 173 patients), respectively (risk ratio, 0.36; 95% CI, 0.12–1.04; P = 0.0599). The incidence rate of cholangitis was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08–0.87; P = 0.0267). DISCUSSION: Antibiotic prophylaxis before ERCP in patients with biliary obstruction resulted in a significantly lower risk of infectious complications, especially cholangitis, than placebo (ClinicalTrials.gov trial number NCT02958059).

31 December 2019 in Journal of dental hygiene science
Verified
Journal Article
Open access
PDF file
MJMoon-Jin Jeong
Moon-Jin Jeong
MLMyoung-Hwa Lee
Myoung-Hwa Lee
SJSoon-Jeong Jeong
Soon-Jeong Jeong
SKSo Jeong Kim
So Jeong Kim
MKMyeong-Ji Ko
Myeong-Ji Ko
DLDo-Seon Lim
Do-Seon Lim
Moon-Jin Jeong, Myoung-Hwa Lee, Soon-Jeong Jeong, So-Jeong Kim, Myeong-Ji Ko, Hye-Won Sim, Ju-Young Lee, Ae-Jung Im, and Do-Seon Lim. J Dent Hyg Sci 2019;19:261-70. https://doi.org/10.17135/jdhs.2019.19.4.261

22 December 2023 in Gut and Liver
Verified
Journal Article
Open access
PDF file
DJDong Kee Jang
Dong Kee Jang
SKSo Jeong Kim
So Jeong Kim
HCHwe Hoon Chung
Hwe Hoon Chung
JLJae Min Lee
Jae Min Lee
SYSeung Bae Yoon
Seung Bae Yoon
KCKorean Society Of Gastrointestinal Cancer
Korean Society Of Gastrointestinal Cancer
Dong Kee Jang, So Jeong Kim, Hwe Hoon Chung, Jae Min Lee, Seung Bae Yoon, Jong-Chan Lee, Dong Woo Shin, Jin-Hyeok Hwang, Min Kyu Jung, Yoon Suk Lee, Hee Seung Lee, Joo Kyung Park, Korean Society of Gastrointestinal Cancer. Gut and Liver 2024;18:729-36. https://doi.org/10.5009/gnl230164

3 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Chan Su ParkChan Su Park
Chan Su Park
MSMin Je Sung
Min Je Sung
SKSo Jeong Kim
So Jeong Kim
JJJung Hyun Jo
Jung Hyun Jo
HLHee Seung Lee
Hee Seung Lee
JPJeong Youp Park
Jeong Youp Park
Some BTC types respond to pembrolizumab, but there are no known prognostic factors to predict its treatment benefits. In this study, we attempted to identify the prognostic factors associated with pembrolizumab as a second-line treatment for gemcitabine-refractory BTC. This retrospective and single tertiary-center study involved all the consecutive patients (n = 80) with refractory advanced BTC, who were diagnosed as programmed cell death ligand 1-positive and treated with pembrolizumab between August 2017 and February 2021. The overall survival (OS) was analyzed using Cox regression analysis. The median OS was 6.0 months [95% confidence interval (CI): 3.87–8.20]; median progression-free survival was 1.9 months (95% CI: 1.82–1.98); and the response rate was 15.9%. In the multivariate Cox regression analysis, the TB [adjusted hazard ratio (HR) = 2.286; 95% CI: 1.177–4.440; p = 0.015), albumin levels (adjusted HR = 0.392; 95% CI: 0.211–0.725; p = 0.003), ALP levels (adjusted HR = 1.938; 95% CI: 1.105–3.400; p = 0.021), and LMR (adjusted HR = 0.325; 95% CI: 0.173–0.609; p < 0.001) were identified as significant variables associated with the OS. High albumin levels and LMR and low ALP levels and TB were significantly associated with better OS in patients treated with pembrolizumab.